<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6514695\results\search\disease\results.xml">
  <result pre="virus and dengue virus), togaviruses (Chikungunya virus and Mayaro virus)," exact="influenza" post="virus, human immunodeficiency virus, and hepatitis B virus. This"/>
  <result pre="virus and Mayaro virus), influenza virus, human immunodeficiency virus, and" exact="hepatitis" post="B virus. This review will describe some of the"/>
  <result pre="the extract possesses potent antiviral activities against numerous viruses, particularly" exact="hepatitis" post="C virus (HCV). Consequently, silymarin is the most commonly"/>
  <result pre="the European Medicines Agency (EMA) for the prevention of recurrent" exact="hepatitis" post="C in liver transplant recipients in 2010 [5]. To"/>
  <result pre="are (+)ssRNA viruses that include important human pathogens such as" exact="hepatitis" post="C virus (HCV) and dengue virus (DENV). HCV is"/>
  <result pre="C) that can lead to end-stage liver diseases such as" exact="cirrhosis" post="and hepatocellular carcinoma (HCC) [6]. DENV, on the other"/>
  <result pre="can lead to end-stage liver diseases such as cirrhosis and" exact="hepatocellular carcinoma" post="(HCC) [6]. DENV, on the other hand, is the"/>
  <result pre="DENV, on the other hand, is the etiologic agent of" exact="dengue fever" post="(DF) and the more severe dengue hemorrhagic fever (DHF)"/>
  <result pre="etiologic agent of dengue fever (DF) and the more severe" exact="dengue hemorrhagic fever" post="(DHF) and dengue shock syndrome (DSS), which are fatal"/>
  <result pre="significant cytotoxicity. Further examination revealed that the silymarin-mediated inhibition of" exact="influenza" post="replication occurred through inhibition of late mRNA synthesis. However,"/>
  <result pre="whether or not silymarin could modulate other phases of the" exact="influenza" post="life cycle was not investigated. The other study that"/>
  <result pre="al. [23]. Due to the importance of autophagy in promoting" exact="influenza" post="replication, these authors elegantly designed a bimolecular fluorescence complementation-fluorescence"/>
  <result pre="IAV replication as well as several physiological processes induced by" exact="influenza" post="replication, such as oxidative stress and the activation of"/>
  <result pre="the HeLa cell line TZM-bl, PBMCs, and the human T" exact="lymphoblastic leukemia" post="cell line CME in vitro. Mechanistic studies revealed that"/>
  <result pre="HeLa cell line TZM-bl, PBMCs, and the human T lymphoblastic" exact="leukemia" post="cell line CME in vitro. Mechanistic studies revealed that"/>
  <result pre="year due to the HBV-associated end-stage liver diseases such as" exact="cirrhosis" post="and HCC [30]. Although effective vaccines against the virus"/>
  <result pre="contrast, silymarin treatment could not block the progression of established" exact="cancer" post="in mice and had no significant effect on the"/>
  <result pre="we review the antiviral effect of silymarin-associated drugs in chronic" exact="hepatitis" post="C, liver transplantation, and difficult-to-treat HIV/HCV coinfected patients. 3.1."/>
  <result pre="of silymarin or its component silibinin in patients with chronic" exact="hepatitis" post="C. Oral administration of silymarin capsules ranging from 140"/>
  <result pre="treatment dose-dependently and continuously decreased HCV viral load in chronic" exact="hepatitis" post="C patients who were previously non-responders to the Peg-IFN+RBV"/>
  <result pre="Following Ferenci’s study, Biermer et al. also reported a successful" exact="suppression" post="of HCV viremia to undetectable level in a Peg-IFN+RBV"/>
  <result pre="IFN-containing treatments. 3.2. Liver Transplantation in Hepatitis C HCV-associated liver" exact="cirrhosis" post="and HCC are common indications for liver transplantation. The"/>
  <result pre="volunteers [62]. The recent phase II trial demonstrated in chronic" exact="hepatitis" post="C patients who received silymarin capsules that serum level"/>
  <result pre="which likely affected the efficacy outcome of the drug against" exact="hepatitis" post="C [35]. The above factors contribute to the poor"/>
  <result pre="most clinical trials and case studies, including those against chronic" exact="hepatitis" post="C and HIV/HCV coinfection, employed the more water-soluble salt-derivatives"/>
  <result pre="accumulation in the liver highlight an advantage for application against" exact="viral hepatitis," post="including hepatitis C, and underscores its potency for further"/>
  <result pre="liver highlight an advantage for application against viral hepatitis, including" exact="hepatitis" post="C, and underscores its potency for further development as"/>
  <result pre="hepatoprotective and antiviral activity makes them ideal candidates, particularly for" exact="hepatitis" post="C with the greatest number of preclinical and clinical"/>
  <result pre="a potential treatment strategy, particularly for the treatment of chronic" exact="viral hepatitis." post="Further research to improve the bioavailability, delivery, as well"/>
  <result pre="https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu310828(accessed on 23 March 2019) 6.AlterH.J.SeeffL.B.Recovery, persistence, and sequelae in" exact="hepatitis" post="C virus infection: A perspective on long-term outcomeSemin. Liver"/>
  <result pre="long-term outcomeSemin. Liver Dis.200020173510895429 7.FrancoL.PalaciosG.MartinezJ.A.VázquezA.SavjiN.De OryF.Sanchez-SecoM.P.MartínD.LipkinW.I.TenorioA.First report of sylvatic DENV-2-associated" exact="dengue hemorrhagic fever" post="in West AfricaPLoS Negl. Trop. Dis.20115e125110.1371/journal.pntd.000125121829739 8.PolyakS.J.MorishimaC.ShuhartM.C.WangC.C.LiuY.LeeD.Y.Inhibition of T-Cell"/>
  <result pre="of Hepatitis C Virus RNA-Dependent RNA PolymeraseGastroenterology20101381112112210.1053/j.gastro.2009.11.05319962982 12.BlaisingJ.LévyP.L.GondeauC.PhelipC.VarbanovM.TeissierE.RuggieroF.PolyakS.J.OberliesN.H.IvanovicT.et al.Silibinin inhibits" exact="hepatitis" post="C virus entry into hepatocytes by hindering clathrin-dependent traffickingCell."/>
  <result pre="into hepatocytes by hindering clathrin-dependent traffickingCell. Microbiol.2013151866188210.1111/cmi.1215523701235 13.Esser-NobisK.Romero-BreyI.GantenT.M.GouttenoireJ.HarakC.KleinR.SchemmerP.BinderM.SchnitzlerP.MoradpourD.et al.Analysis of" exact="hepatitis" post="C virus resistance to Silibinin in vitro and in"/>
  <result pre="silybin fatty acid conjugatesEur. J. Med. Chem.2010451059106710.1016/j.ejmech.2009.11.05620036447 22.SongJ.ChoiH.Silymarin efficacy against" exact="influenza" post="A virus replicationPhytomedicine20111883283510.1016/j.phymed.2011.01.02621377857 23.DaiJ.-P.WuL.-Q.LiR.ZhaoX.-F.WanQ.-Y.ChenX.-X.LiW.-Z.WangG.-F.LiK.-S.Identification of 23-(S)-2-Amino-3-Phenylpropanoyl-Silybin as an Antiviral"/>
  <result pre="its association with enhancement of phase II enzymes: Implications in" exact="cancer" post="chemopreventionCarcinogenesis1999202101210810.1093/carcin/20.11.210110545412 25.RoeB.HallW.W.Cellular and molecular interactions in coinfection with hepatitis"/>
  <result pre="in cancer chemopreventionCarcinogenesis1999202101210810.1093/carcin/20.11.210110545412 25.RoeB.HallW.W.Cellular and molecular interactions in coinfection with" exact="hepatitis" post="C virus and human immunodeficiency virusExpert Rev. Mol. Med.2008101010.1017/S1462399408000847"/>
  <result pre="on cellular metabolismVirology20144499610310.1016/j.virol.2013.11.00324418542 28.LaniR.HassandarvishP.ChiamC.W.MoghaddamE.ChuJ.J.H.RausaluK.MeritsA.HiggsS.VanLandinghamD.Abu BakarS.et al.Antiviral activity of silymarin against" exact="chikungunya" post="virusSci. Rep.201551142110.1038/srep1142126078201 29.CaminiF.C.Da SilvaT.F.CaetanoC.C.D.S.AlmeidaL.T.FerrazA.C.VitoretiV.M.A.SilvaB.D.M.SilvaS.D.Q.De MagalhãesJ.C.MagalhãesC.L.D.B.Antiviral activity of silymarin against"/>
  <result pre="American ParentsJ. Immigr. Minor. Heal.20172094395010.1007/s10903-017-0609-128639095 31.UmetsuT.InoueJ.KogureT.KakazuE.NinomiyaM.IwataT.TakaiS.NakamuraT.SanoA.ShimosegawaT.Inhibitory effect of silibinin on" exact="hepatitis" post="B virus entryBiochem. Biophys. Rep.201814202510.1016/j.bbrep.2018.03.00329872730 32.WuY.-F.FuS.-L.KaoC.-H.YangC.-W.LinC.-H.HsuM.-T.TsaiT.-F.Chemopreventive Effect of Silymarin"/>
  <result pre="MiceCancer Res.2008682033204210.1158/0008-5472.CAN-07-245018339886 33.TanamlyM.TadrosF.LabeebS.MakldH.MikhailN.Abdel-HamidM.ShehataM.Abu-BakiL.MedhatA.MagderL.et al.Randomised double-blinded trial evaluating silymarin for chronic" exact="hepatitis" post="C in an Egyptian village: Study description and 12-month"/>
  <result pre="description and 12-month resultsDig. Liver Dis.20043675275910.1016/j.dld.2004.06.01515571006 34.GabbayE.ZigmondE.PappoO.HemedN.RoweM.ZabreckyG.CohenR.IlanY.Antioxidant therapy for chronic" exact="hepatitis" post="C after failure of interferon: Results of phase II"/>
  <result pre="trialWorld J. Gastroenterol.2007135317532310.3748/wjg.v13.i40.531717879400 35.FriedM.W.NavarroV.J.AfdhalN.BelleS.H.WahedA.S.HawkeR.L.DooE.MeyersC.M.ReddyK.R.SilymarinN.et al.Effect of silymarin (milk thistle) on" exact="liver disease" post="in patients with chronic hepatitis C unsuccessfully treated with"/>
  <result pre="silymarin (milk thistle) on liver disease in patients with chronic" exact="hepatitis" post="C unsuccessfully treated with interferon therapy: A randomized controlled"/>
  <result pre="al.Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic" exact="hepatitis" post="C treated with pegylated interferon alpha and ribavirinAm. J."/>
  <result pre="39.FerenciP.ScherzerT.M.KerschnerH.RutterK.BeinhardtS.HoferH.Schöniger–HekeleM.HolzmannH.Steindl–MundaP.Silibinin is a potent antiviral agent in patients with chronic" exact="hepatitis" post="C not responding to pegylated interferon/ribavirin therapyGastroenterology20081351561156710.1053/j.gastro.2008.07.07218771667 40.GuedjJ.DahariH.PohlR.-T.FerenciP.PerelsonA.S.Understanding silibinin’s"/>
  <result pre="RecipientsAvailable online: https://www.uptodate.com/contents/hepatitis-c-virus-infection-in-liver-transplant-candidates-and-recipients(accessed on 10 March 2019) 46.NeumannU.BiermerM.EurichD.NeuhausP.BergT.Successful prevention of" exact="hepatitis" post="C virus (HCV) liver graft reinfection by silibinin mono-therapyJ."/>
  <result pre="infection after orthotopic liver transplantation in a patient with chronic" exact="hepatitis" post="CJ. Hepatol.20115459159210.1016/j.jhep.2010.09.00921106270 48.EurichD.BahraM.BergT.Boas-KnoopS.BiermerM.NeuhausR.NeuhausP.NeumannU.Treatment of hepatitis C-virus-reinfection after liver transplant"/>
  <result pre="in a patient with chronic hepatitis CJ. Hepatol.20115459159210.1016/j.jhep.2010.09.00921106270 48.EurichD.BahraM.BergT.Boas-KnoopS.BiermerM.NeuhausR.NeuhausP.NeumannU.Treatment of" exact="hepatitis" post="C-virus-reinfection after liver transplant with silibinin in nonresponders to"/>
  <result pre="with silibinin, pegylated interferon and ribavirin in a patient with" exact="hepatitis" post="C virus genotype 3 reinfection after liver transplantation: A"/>
  <result pre="Nanosci. Nanotechnol.2012122022202710.1166/jnn.2012.517322755015 76.PolyakS.J.FerenciP.PawlotskyJ.M.Hepatoprotective and antiviral functions of silymarin components in" exact="hepatitis" post="C virus infectionHepatology2013571262127110.1002/hep.2617923213025 Figure 1 Chemical structures of silibinin,"/>
 </snippets>
</snippetsTree>
